Dr Munshi on the Background of the CARTITUDE-1 Trial in Mult

Nikhil C. Munshi, MD, discusses the background of the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and highlights the specific patient population enrolled in the study.

Related Keywords

Nikhilc Munshi , , Dana Farber Cancer Institute , Medicine At Harvard Medical School , Correlative Science , Jerome Lipper Multiple Myeloma Center , Kraft Family Chair , Multiple Myeloma Immune Effector Cell Therapy , Harvard Medical School , Multiple Myeloma , Onclive Tv ,